PDCD1 and neoplasm: The PD-1 cell surface receptor is expressed on tumor-infiltrating immune cells and its ligand, PD-L1, is expressed on antigen-presenting cells and tumor cells, forming an interacting immune checkpoint axis that blocks the adaptive immune response against tumor cells and thereby enabling immune evasion [18].